TG Therapeutics (NASDAQ: TGTX) reported Q4 EPS of ($0.39), $0.12 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $80 thousand versus the consensus estimate of $1.83 million.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.